Pestalozzi and Ropes & Gray advised Johnson & Johnson on a USD 500 million R&D co-funding agreement with Royalty Pharma to advance the development of JNJ-4804, an investigational co-antibody therapy targeting autoimmune diseases.
Tags :Johnson & Johnson
